This study helps us understand epilepsy in people with tuberous sclerosis complex (TSC) by analysing the experiences of 1852 people with both TSC and epilepsy involved in the TOSCA project.
We are pleased to share news that everolimus (Afinitor) for epilepsy has been added to Australia’s pharmaceutical benefits scheme (PBS). Today the Federal Health Minister, the Honourable Greg Hunt announced that this medicine to treat seizures for people with TSC … Read More
Dr Bec Mitchell continues her valuable work on the DOTS* study that is increasing our knowledge of the risk factors for autism in children with TSC and of possible interventions for children at risk of autism. Dr Mitchell is a … Read More
We are pleased to share news that Everolimus (Afinitor) for epilepsy has been given a positive recommendation by the pharmaceutical benefits advisory committee (PBAC). This is a recommendation to the Federal Health Minister to add this medicine to the pharmaceutical … Read More
Today we celebrate the academic publication of results from the Treatment trial. This research developed a topical cream to treat the small tumours that grow on the face of people with tuberous sclerosis. While these tumours, called angiofibromas, do … Read More
Invitation to TSC families in NSW and ACT to participate in this focus group study.
Dr Denise Chan spoke with TSA’s General Manager, Clare Stuart First of all, congratulations on your recent travel award to the International TSC Research Conference. What was your TSC research project about? Thanks! I am a paediatric neurology fellow at … Read More
Many families with TSC struggle with challenging behaviours. This study aims to understand not only which behaviours are associated with Tuberous Sclerosis Complex, but also which behaviours are of most concern to parents and caregivers. Please see the flyer for more … Read More
A selection of recently published articles with a focus on high impact and Australian TSC research. Summaries written by Kate Fessey and Clare Stuart. This article was first published in the October 2016 issue of Reach Out, TSA’s twice-yearly magazine. … Read More
Clare Stuart, general manager, TSA. In addition to early surveillance and surgery, there are two other areas of research that have the potential to deliver new treatment options for people with epilepsy caused by tuberous sclerosis: mTOR inhibitor medicine and … Read More